An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data

IVFarma LLC5,484 enrolled

Overview

Aim to investigate the efficacy of follitropin alpha biosimilar therapy (Primapur®) in nonselected real-world population.

A retrospective observational anonymized cohort study of follitropin alpha biosimilar (Primapur®) as a pre-filled pen injector with a dose adjustment of 5 IU, aimed to investigate its efficacy and safety in a nonselected population with indications to assisted reproductive technologies (ART) was carried out. The ovarian stimulation (OS) protocols included: monotherapy protocols with using only Primapur®; mixed protocols (recombinant and urinary-derived gonadotropins); short protocols with using antagonists of gonadotropin-releasing hormone (GnRH) and long protocols with GnRH agonists. The stimulation protocols were analyzed with Primapur® application for at least 5 days.

Study Type

OBSERVATIONAL

Enrollment

5,484

Conditions

Reproductive Issues Reproductive Disorder Fertility Disorders Fertility Issues Gynecologic Disease IVF

Interventions

Follitropin AlfaDRUG

Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH or agonist of GnRH.

Follicle Stimulating Hormone/Luteinizing HormoneDRUG

Subcutaneous injection of follitropin alpha biosimilar, with daily dose 100-300 IU for at least 5 days, than added another gonadotropin for a maximum of 10 days, using antagonists of GnRH or agonist of GnRH.

Follitropin AlfaDRUG

Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH only for suppression.

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 43 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women with established causes of infertility and indications for the use of ART methods, according to the Order of the Ministry of Health of the Russian Federation "On the use of assisted reproductive technologies, contraindications and limitations to their use" No. 107 n dated August 30, 2012. * Infertility due to female and/or male factor. * Presence of ovaries accessible for aspiration of follicles. * Anatomical and functional capability of uterus to bear pregnancy. Exclusion Criteria: * Women with established contraindications to the use of ART methods, according to the Order of the Ministry of Health of the Russian Federation "On the use of assisted reproductive technologies, contraindications and limitations to their use" No. 107 n dated August 30, 2012. * Presence of pregnancy * Hypersensitivity to follitropin alfa or excipients. * Ovarian cysts (not associated with polycystic ovarian syndrome), uterine hemorrhage of unclear etiology * Premature ovarian failure * Presence of clinically significant systemic disease * Presence of chronic cardiovascular, hepatic, renal or pulmonary disease * Neoplasia * Narcomania, alcoholism

Locations (35)

Outcomes

Primary Outcomes

Number of Oocytes Retrieved

The total number of retrieved oocytes at the day of ovum pick-up. No more than 37 hours from the introduction of the ovulation inducer (HCG or GnRH-agonist). Due to lack of efficacy of the therapy (ovarian stimulation was not completed and oocytes were not retrieved) the analysed population was: (1) Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH - 2625 participants (lack of efficacy: 78 participants, the analysed population was 2547 participants); (2) Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH - 2859 participants (lack of efficacy: 89, the analysed population was 2770); (3) Monoprotocols: follitropin alpha biosimilar only and antagonists of GnRH - 2183 participants (lack of efficacy: 59, the analysed population was 2124) and (4) Monoprotocols: follitropin alpha biosimilar only and agonist of GnRH - 676 participants (lack of efficacy: 30, the analysed population was 646).

Time frame: From date of start of ovarian stimulation with follitropin alpha up to 15 days

Percentage of Participants With Ongoing Clinical Pregnancy Per Embryo Transfer

Ongoing clinical pregnancy per embryo transfer (detection of gestational sac and heartbeat from 6 weeks after transfer), n (ongoing pregnancy rate per transfer with known outcome, %). Due to delayed embryo transfers, the analysed population for "Ongoing clinical pregnancy per embryo transfer" was: (1) Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH - 2007 embryo transfers (1542 with known outcome); (2) Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH - 2213 embryo transfers (1800 with known outcome); (3) Monoprotocols: follitropin alpha biosimilar only and antagonists of GnRH - 1809 embryo transfers (1466 with known outcome) and (4) Monoprotocols: follitropin alpha biosimilar only and agonist of GnRH - 404 embryo transfers (334 with known outcome).

Time frame: At least 6 weeks after embryo transfer

Secondary Outcomes

Number of Mature Oocytes

Mature oocytes (MII stage of development). Due to lack of efficacy of the therapy (ovarian stimulation was not completed and oocytes were not retrieved) the analysed population was: (1) Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH - 2625 participants (lack of efficacy: 78 participants, the analysed population was 2547 participants); (2) Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH - 2859 participants (lack of efficacy: 89, the analysed population was 2770); (3) Monoprotocols: follitropin alpha biosimilar only and antagonists of GnRH - 2183 participants (lack of efficacy: 59, the analysed population was 2124) and (4) Monoprotocols: follitropin alpha biosimilar only and agonist of GnRH - 676 participants (lack of efficacy: 30, the analysed population was 646).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Center for reproductive medicine, Barnaul

Barnaul, Russia

Center for reproductive medicine, Irkutsk

Irkutsk, Russia

Clinic "Mother and Child" Kazan

Kazan', Russia

Clinic "Mother and Child" Kostroma

Kostroma, Russia

Clinic "Mother and Child" Krasnodar

Krasnodar, Russia

Center for reproductive medicine, Krasnoyarsk

Krasnoyarsk, Russia

AltraVita IVF clinic

Moscow, Russia

Center of Reproductive Medicine and Genetics "Nova Clinic"

Moscow, Russia

Clinic "Mather and Child" Lefortovo

Moscow, Russia

Clinic "Mather and Child" Savelovskaya

Moscow, Russia

...and 25 more locations